Tillotts Pharma AG announces the launch of Octasa® 1600 mg tablets in Canada
07 April 2023 | Friday | News
Tillotts Pharma AG ("Tillotts"), part of the Japanese Zeria Group, is pleased to announce the recent launch of Octasa® 1600 mg (mesalazine) delayed-release tablets as first-line treatment for moderately active ulcerative colitis (UC) in Canada.
The expansion of the Octasa® family in Canada with the launch of Octasa® 1600 mg represents an important step in the strategic partnership of Tillotts Pharma AG with Pendopharm and a milestone for both organizations.
The introduction of Octasa® 1600 mg (mesalazine) delayed-release tablets to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Adrian Hill, Global Head of Commercial Operations at Tillotts, said:
"Tillotts has a longstanding history of more than 40 years in delivering mesalazine formulations for the treatments of patients suffering from UC, and I am very excited about the opportunity to strengthen our commercial presence in Canada by launching Octasa® 1600 mg tablet as a new high strength mesalazine tablet treatment option.
This has been achieved through the solid strategic partnership between Tillotts and Pendopharm."
Jad Isber, Vice President and General Manager at Pendopharm, added:
"Earlier this year, we announced the launch of Octasa® 800 mg, and we are delighted to continue our strong relationship with Tillotts by bringing Octasa® 1600 mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa® 1600 mg to our portfolio will further enhance Pendopharm’s leadership position in gastroenterology, bringing a new treatment option to healthcare professionals and patients."
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
